特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
353893

世界の腎癌治療薬および診断市場 - 癌タイプ、治療薬、診断法、エンドユーザー、地域別

Kidney Cancer Therapeutics & Diagnostics Market- Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円
世界の腎癌治療薬および診断市場 - 癌タイプ、治療薬、診断法、エンドユーザー、地域別
出版日: 2020年08月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の腎癌治療薬および診断市場は、2018年から2023年にかけて10.5%のCAGRで推移することが予測されています。腎癌は最も頻度の高い癌のひとつで、その中でも腎細胞癌の占める割合はここ数年で徐々に増加しています。当市場の主な成長要因には、高齢化、飲酒量の増加、喫煙、生活習慣の変化、政府による腎癌治療に対する取組みなどが挙げられます。

当レポートでは、世界の腎癌治療薬および診断市場を調査し、市場の概要、癌タイプ・治療薬・診断法・エンドユーザー・地域別の市場規模の推移と予測、成長要因・阻害要因ならびに市場機会・課題の分析、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な影響要因

第5章 市場の概要

  • 現在の市場シナリオ
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第6章 成長要因、阻害要因、機会、課題の分析

  • 成長要因
    • 腎がん症例数の増加
    • 製薬企業における研究開発費の増加
    • 高齢化と慢性疾患の罹患率の上昇
  • 阻害要因
    • 治療に関連するコストの高さ
    • 癌治療薬の臨床試験の成功率の低さ
    • 規制上の問題
  • 市場機会
  • 主な課題

第7章 市場セグメンテーション

  • 癌タイプ別
    • 腎細胞癌
    • 淡明細胞型腎細胞癌
    • 乳頭状腎細胞癌
    • 嫌色素性腎細胞癌
    • その他
  • 治療薬別
    • アフィニトール
    • アバスチン
    • インライタ
    • ネクサバール
    • プロロイキン
    • ヴォトリエント
    • スーテント
  • 診断法別
    • 生検
    • 静脈瘤
    • CTスキャン
    • 腎臓・尿管鏡検査法
    • 超音波
    • その他
  • エンドユーザー別
    • 病院
    • 製薬ラボ
    • ゲノミクスラボ
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第8章 競合情勢

  • 合併および買収分析
  • 合意、コラボレーション、パートナーシップ
  • 新製品の発売

第9章 主要企業のプロファイル

  • Abbott Laboratories
  • Amgen
  • Bayer Healthcare
  • Cerulean Pharma
  • F. Hoffmann-La Roche
  • Genentech
  • GlaxoSmithKline
  • Novartis
  • Pfizer
  • Seattle Genetics
  • リストは網羅的ではありません

第10章 市場の将来展望

目次
Product Code: 53395

The kidney cancer therapeutics & diagnostics market will show a rapid growth due to the rising number of kidney cancer cases and increased R&D expenditure of the pharmaceutical companies.

  • According to the GLOBOCAN, the incidence of Kidney cancer is 4.5 per 100,000 in 2018, worldwide. The 5 major countries contributing to the global cancer cases are China, the United States, Russia, Germany, and Japan. These countries are found to have the highest cases of kidney cancer worldwide.
  • The increasing kidney cancer cases globally is expected to increase the demand for diagnostic methods for early-stage treatment worldwide. As per the American Cancer Society's recent estimates, in 2019, there were about 73,820 new cases of kidney cancer (44,120 in men and 29,700 in women). Kidney and renal pelvis cancer represent 4.2% of all new cancer cases in the United States. It was estimated that there were around 14,770 deaths in 2019, owing to Kidney and renal pelvis cancer.
  • Currently, there are various treatment options available and many drugs are in pipeline too, which is expected to drive the kidney cancer therapeutics and diagnostics market during the forecast period.
  • In addition, rising investments in research by various government bodies and development of novel drugs by pharmaceutical and biotechnology companies are other major contributing factors.

Key Market Trends

Clear cell RCC is Expected to be the Largest Growing Segment in the Kidney Cancer Therapeutics & Diagnostics Market

  • Clear cell renal cell carcinoma, or ccRCC, is a type of kidney cancer. Clear cell renal cell carcinoma is also called conventional renal cell carcinoma. Clear cell renal cell carcinoma is named after how the tumor looks under the microscope. The cells in the tumor look clear, like bubbles.
  • As per the National Cancer Institute of the United States, in adults, ccRCC is the most common type of kidney cancer and makes up about 80% of all renal cell carcinoma cases. ccRCC is more common in adults than in children. Renal cell carcinoma makes up 2% to 6% of childhood and young adult kidney cancer cases.
  • Patients with ccRCC may have pain or feel tired. Sometimes, patients do not have any noticeable symptoms. Symptoms can include blood in the urine, pain, weight loss, feeling tired, fever, and a lump in the side.
  • For people without symptoms, these tumors can be discovered if the person has an imaging test as well. Another method to detect ccRCC is biopsy. To check if the tumor is ccRCC, the physician performs a biopsy, taking a small sample from the tumor with a needle. The sample is studied under the microscope to see what kind of tumor it is.
  • Treatments for people with ccRCC include surgery, immunotherapy, and targeted therapy. Targeted therapy targets the changes in cancer cells that help them grow, divide, and spread. Some targeted therapies that are used to treat clear cell renal carcinoma include cabozantinib, axitinib, sunitinib, sorafenib, and pazopanib.
  • Hence, with high prevalence of the disease and presence of diagnostic procedures and treatment therapies, the market is expected to witness growth.

North America is found to be Leading the Kidney Cancer Therapeutics & Diagnostics Market

North America dominates the global kidney cancer therapeutics and diagnostics market. The major factor driving the growth is the increasing number of kidney cancer cases. As per the GLOBOCAN 2018 statistics, estimated number of kidney cancer were 60,336 in the United States. Other factors, such as increased R&D expenditure of pharmaceutical companies and increasing incidences of aging population, are expected to lead to the growth of the market in the forecast period.

However, the region of Asia-Pacific is expected to be the fastest growing market during the forecast period. Rising patient base suffering from renal cancer, growing patient awareness and lower costs of drug production are expected to drive the growth of this market.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. Product innovation and ongoing R&D activities to develop advanced technologies has helped in boosting the growth of the market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Kidney Cancer
    • 4.2.2 Increased R&D Expenditure of Pharmaceutical Companies
  • 4.3 Market Restraints
    • 4.3.1 High Cost Associated with Treatment
    • 4.3.2 Low Success Rate in Clinical Trials for Cancer Drugs
    • 4.3.3 Regulatory Issues
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Cancer Type
    • 5.1.1 Clear cell RCC
    • 5.1.2 Papillary RCC
    • 5.1.3 Chromophobe RCC
    • 5.1.4 Urothelial carcinoma/Transitional cell carcinoma
    • 5.1.5 Other Kidney cancers (Wilms tumor, Renal sarcoma, Collecting duct RCC)
  • 5.2 By Component
    • 5.2.1 Drugs
      • 5.2.1.1 Therapeutic Class
      • 5.2.1.1.1 Targeted Therapy
      • 5.2.1.1.2 Immunotherapy
      • 5.2.1.1.3 Other Therapeutic Class
      • 5.2.1.2 By Pharmacologic Class
      • 5.2.1.2.1 Angiogenesis Inhibitors
      • 5.2.1.2.2 Monoclonal Antibodies
      • 5.2.1.2.3 mTOR Inhibitors
      • 5.2.1.2.4 Cytokine Immunotherapy (IL-2)
    • 5.2.2 Diagnostics
      • 5.2.2.1 Biopsy
      • 5.2.2.2 Imaging Tests
      • 5.2.2.3 Blood Tests
      • 5.2.2.4 Other Diagnostics
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott Laboratories
    • 6.1.2 Amgen Inc.
    • 6.1.3 Bayer AG
    • 6.1.4 BRISTOL-MYERS SQUIBB COMPANY
    • 6.1.5 F. Hoffmann-La Roche
    • 6.1.6 Merck & Co. Inc.
    • 6.1.7 Merck KGaA (EMD Serono)
    • 6.1.8 Novartis International AG
    • 6.1.9 Pfizer Inc.
    • 6.1.10 Seattle Genetic

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.